Premenopausal Patients with Node-Positive Resectable Breast Cancer
- 1 January 1993
- journal article
- clinical trial
- Published by Springer Nature in Drugs
- Vol. 45 (2) , 38-45
- https://doi.org/10.2165/00003495-199300452-00007
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer.1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.1992
- Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.Journal of Clinical Oncology, 1990
- Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.Journal of Clinical Oncology, 1989
- A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.Journal of Clinical Oncology, 1988
- Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles.Journal of Clinical Oncology, 1983
- Combination Chemotherapy as an Adjuvant Treatment in Operable Breast CancerNew England Journal of Medicine, 1976
- L-Phenylalanine Mustard (L-PAM) in the Management of Primary Breast CancerNew England Journal of Medicine, 1975